<DOC>
	<DOCNO>NCT02079545</DOCNO>
	<brief_summary>The purpose study assess bioavailability ( extent medication become available body ) subcutaneously ( skin use needle ) administer sirukumab compare pharmacokinetics sirukumab administer subcutaneously use pre-filled syringe fit UltraSafe Passive™ Delivery system ( PFS-U ) SmartJect™ Autoinjector ( PFS-AI ) healthy male participant .</brief_summary>
	<brief_title>Bioavailability Pharmacokinetics Study Sirukumab Healthy Male Participants</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , open-label ( people know identity intervention ) , parallel-group ( group participant treat time ) , multicenter ; single-dose study . Approximately 138 participant randomly allocate 3:3:3:7:7 ratio 1 5 treatment group follow : Group 1 ( single intravenous infusion 100 mg sirukumab ) , Group 2 ( single subcutaneous [ SC ] injection 50 mg sirukumab PFS-U ) , Group 3 ( single SC injection 50 mg sirukumab PFS-AI , Group 4 ( single SC injection 100 mg sirukumab PFS-U ) , Group 5 ( single SC injection 100 mg sirukumab PFS-AI ) . Randomization stratify body weight ( 50.0 kg &lt; 70.0 kg , 70.0 kg &lt; 85.0 kg , 85.0 kg 100.0 kg ) . Participants hospitalize study unit administration study drug discharge completion schedule assessment Day 5 . Participants require return study unit outpatient visit Days 6 7 , follow weekly/biweekly outpatient visit , safety follow-up total 13 week study drug administration . Safety evaluation include assessment adverse event , physical examination , vital sign , injection site infusion reaction , electrocardiogram , clinical laboratory test . The maximum study duration participant 120 day .</detailed_description>
	<criteria>Must weight range 50.0 kg 100.0 kg , inclusive Participant must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram perform screen Each participant must sign informed consent form ( ICF ) indicate understands purpose procedure require study willing participate study Must willing able adhere study visit schedule protocol requirement Must agree abstain alcohol intake 48 hour administration study agent inpatient period study Have know malignancy history malignancy , except nonmelanoma skin cancer treat evidence recurrence least 3 month Day 1 Have know history lymphoproliferative disease , include lymphoma , sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy and/or splenomegaly Have underlying physical psychological medical condition , opinion investigator , would make unlikely participant complete study Have evidence chronic medical condition require prescription medication ( eg , hypertension , elevate cholesterol/triglycerides , asthma , diabetes ) Have history current elevation triglyceride require treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sirukumab</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Male</keyword>
</DOC>